September 03, 2025

FDA Approves Denosumab Biosimilars

The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.

Conexiant

September 03, 2025

Policy Shift Adjusts NIH Peer Review Role

New NIH funding rules shift decision-making power from peer review panels to political appointees in determining future scientific grants.

KFF Health News

September 03, 2025

Study Maps Delta-Like Protein 3 and SEZ6 Across Tumor Types

Researchers highlight distinct Delta-like protein 3 and seizure-related 6 homolog patterns in neuroendocrine tumors.

Conexiant

September 02, 2025

New Bruton’s Tyrosine Kinase Inhibitor Improves Platelet Response

The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.

Conexiant

September 02, 2025

Sotatercept Maintains One-Year Gains in PAH

Ongoing follow-up evaluates long-term sotatercept use in pulmonary arterial hypertension, focusing on sustained efficacy, adverse event profiles, and clinical risk classification.

Conexiant

August 28, 2025

First Generic GLP-1 for Weight Loss Approved

FDA approves Teva’s generic Saxenda (liraglutide) with adult and adolescent indications and a boxed thyroid tumor warning.

Conexiant

August 28, 2025

CD68/CD163 Mark Worse Outcomes in Skeletal Hodgkin Lymphoma, Study

Skeletal classic Hodgkin lymphoma shows a macrophage-rich, B-cell–poor microenvironment, with high CD68/CD163 linked to worse survival.

Conexiant

August 28, 2025

Can Gene Therapy Outperform Implants?

Children receiving gene therapy showed superior hearing and speech perception metrics.

Conexiant

August 28, 2025

Does Changing Biologics Clear Skin Faster?

The psoriasis treatment ladder may not apply to interclass biologic switching.

Conexiant